Mounjaro vs Trulicity: Real-World Evidence Comparison

What Are Mounjaro and Trulicity?

Mounjaro (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist approved by the FDA in May 2022 for type 2 diabetes management. It activates two incretin pathways simultaneously, a mechanism that separates it from every older agent in its class. Trulicity (dulaglutide) is a selective GLP-1 receptor agonist approved in 2014. Both are administered as once-weekly subcutaneous injections, and both lower blood glucose by stimulating insulin secretion, suppressing glucagon, and slowing gastric emptying. FDA approval records for tirzepatide are available at accessdata.fda.gov.

Mechanism: Why Dual Agonism Matters

Tirzepatide's GIP component does more than add a second receptor target. GIP receptors are expressed in adipose tissue and the central nervous system, and preclinical work suggests GIP co-agonism amplifies the weight-lowering signal of GLP-1 activation beyond simple additive effects. Dulaglutide acts only on the GLP-1 receptor, which is still clinically meaningful, GLP-1 receptor agonists as a class reduce A1C by roughly 1.0 to 1.5 percentage points on average, but the ceiling on glucose and weight reduction is lower. The pharmacology of GIP/GLP-1 co-agonism is reviewed in detail at pubmed.ncbi.nlm.nih.gov.

FDA-Approved Indications

Mounjaro is approved for adults with type 2 diabetes as an adjunct to diet and exercise. The same molecule under the brand name Zepbound received FDA approval in November 2023 for chronic weight management in adults with a BMI of 30 or higher, or BMI <27 with at least one weight-related comorbidity. Trulicity is approved only for type 2 diabetes and for cardiovascular risk reduction in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors, a label expansion grounded in REWIND trial data. See the full Trulicity prescribing information at accessdata.fda.gov.

Head-to-Head Trial Evidence: SURPASS-2

SURPASS-2 is the most direct comparison available. Published in the New England Journal of Medicine in 2021, the trial enrolled 1,879 adults with type 2 diabetes inadequately controlled on metformin and randomized them to tirzepatide 5 mg, 10 mg, or 15 mg versus dulaglutide 1.5 mg over 40 weeks. SURPASS-2 full results are indexed at pubmed.ncbi.nlm.nih.gov.

A1C Outcomes

All three tirzepatide doses beat dulaglutide on A1C reduction. The least-squares mean changes from baseline were:

• Tirzepatide 5 mg: -2.01 percentage points
• Tirzepatide 10 mg: -2.24 percentage points
• Tirzepatide 15 mg: -2.46 percentage points
• Dulaglutide 1.5 mg: -1.34 percentage points

The differences versus dulaglutide were -0.67, -0.90, and -1.12 percentage points for the three tirzepatide doses, all statistically significant at P<0.001. A1C <7.0% was achieved by 82%, 87%, and 92% of patients in the tirzepatide arms compared to 52% in the dulaglutide arm. Even at the starting dose of 5 mg, tirzepatide outperformed dulaglutide's maximum approved dose of 1.5 mg.

Weight Loss Outcomes

The weight separation was even more pronounced. Mean body-weight changes from baseline at 40 weeks were -7.6 kg for tirzepatide 5 mg, -9.3 kg for tirzepatide 10 mg, and -11.2 kg for tirzepatide 15 mg, versus -2.3 kg for dulaglutide 1.5 mg. The 15-mg arm produced approximately 12.4 kg more weight loss than the dulaglutide arm. Among tirzepatide 15 mg patients, 27% achieved 15% or more body weight reduction, compared to 1.1% with dulaglutide. Full SURPASS-2 supplementary data available at nejm.org.

Safety and Tolerability in SURPASS-2

Gastrointestinal adverse events (nausea, diarrhea, vomiting) were the most common side effects in both arms. Nausea occurred in 17 to 22% of tirzepatide patients and 18% of dulaglutide patients, with rates largely overlapping at lower tirzepatide doses. Serious adverse events were similar across arms. Hypoglycemia <54 mg/dL occurred in <1% of patients in each arm given the absence of sulfonylureas or insulin in the background regimen.

Cardiovascular Outcomes: Where Trulicity Has the Edge

The REWIND trial remains the definitive cardiovascular outcomes study for dulaglutide. Published in The Lancet in 2019, REWIND enrolled 9,901 adults with type 2 diabetes who had either established cardiovascular disease or multiple risk factors and randomized them to dulaglutide 1.5 mg or placebo over a median follow-up of 5.4 years. REWIND primary results are indexed at pubmed.ncbi.nlm.nih.gov.

REWIND Primary Endpoint

The primary composite endpoint of major adverse cardiovascular events (MACE), nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death, occurred in 12.0% of dulaglutide patients versus 13.4% of placebo patients, a hazard ratio of 0.88 (95% CI 0.79 to 0.99, P=0.026). The Lancet authors noted this benefit applied even in patients without established cardiovascular disease at enrollment, the first GLP-1 agent trial to demonstrate that finding at the time of publication.

Tirzepatide Cardiovascular Data: Current Status

Tirzepatide does not yet have a completed dedicated cardiovascular outcomes trial with published MACE data in the type 2 diabetes population. The SURPASS-CVOT trial (NCT04255433) completed enrollment, and interim analyses are anticipated, but as of mid-2025 full peer-reviewed MACE results are not published. Post-hoc analyses from SURPASS-2 showed numerically fewer cardiovascular events in tirzepatide arms, but the trial was not powered or designed for cardiovascular endpoints. Clinicians managing patients with established atherosclerotic cardiovascular disease should factor this evidence gap into prescribing decisions, particularly when the patient's primary need is MACE risk reduction. Current trial status can be reviewed at the NIH clinical trials registry via nih.gov.

The Semaglutide Comparison Point

Semaglutide 0.5 mg and 1.0 mg (Ozempic) demonstrated MACE benefit in SUSTAIN-6 (HR 0.74, 95% CI 0.58 to 0.95), and semaglutide 2.4 mg (Wegovy) showed a 20% MACE reduction in SELECT (N=17,604, HR 0.80, 95% CI 0.72 to 0.90). SELECT results are published at nejm.org. Tirzepatide's cardiovascular profile may be similar or superior once SURPASS-CVOT is fully reported, but current guideline-based decisions cannot yet assume equivalence.

Real-World Evidence Beyond Randomized Trials

Observational Cohort Data

Randomized trials control confounders but often exclude patients with multiple comorbidities, older age, or renal impairment. Real-world data from pharmacy claims and electronic health records fill that gap. A 2023 retrospective cohort study using U.S. Insurance claims (N=18,386 tirzepatide initiators matched to GLP-1 initiators) found tirzepatide produced statistically greater reductions in A1C and body weight at 6 and 12 months compared to GLP-1-only agents including dulaglutide, consistent with trial findings. Real-world GLP-1 comparative data are indexed at pubmed.ncbi.nlm.nih.gov.

Persistence and Adherence

Medication persistence at 12 months differs between agents. Real-world analyses suggest tirzepatide persistence rates of approximately 55 to 65% at one year, while dulaglutide persistence in older real-world datasets was roughly 45 to 55%, differences driven partly by efficacy satisfaction and partly by cost and formulary access. Neither figure is particularly high, which underscores that the best medication is the one the patient can consistently access and tolerate.

Renal Impairment Populations

Both agents can be used in patients with chronic kidney disease. Dulaglutide has longer published safety data across CKD stages and was specifically studied in AWARD-7, which enrolled patients with eGFR 15 to 60 mL/min/1.73m2. AWARD-7 results are at pubmed.ncbi.nlm.nih.gov. Tirzepatide does not require dose adjustment for renal impairment per its prescribing information, but trial representation of patients with severe CKD (eGFR <30) remains limited relative to the dulaglutide evidence base.

Dosing, Titration, and Administration

Tirzepatide Dosing Schedule

The FDA-approved titration for tirzepatide starts at 2.5 mg subcutaneously once weekly for 4 weeks, then increases to 5 mg once weekly. Further uptitration in 2.5-mg increments every 4 weeks is optional, with maximum doses of 10 mg and 15 mg available for patients who need additional glycemic or weight control. The dose-response relationship is clear: each step up produces incremental A1C and weight benefit, though gastrointestinal tolerability decreases at higher doses. Full tirzepatide prescribing information at accessdata.fda.gov.

Dulaglutide Dosing Schedule

Dulaglutide starts at 0.75 mg subcutaneously once weekly. After 4 weeks, the dose may be increased to 1.5 mg, and in 2020 the FDA approved a 3.0 mg and 4.5 mg dose for patients requiring further glycemic control, based on AWARD-11 trial data. AWARD-11 results are indexed at pubmed.ncbi.nlm.nih.gov. The higher doses (3.0 mg and 4.5 mg) are not available as the standard pre-filled Trulicity pen in all markets, and prescribers should verify formulary coverage.

Device Differences

Both drugs use autoinjector pens. Trulicity's single-use autoinjector conceals the needle entirely, which many needle-anxious patients find preferable. Mounjaro uses a KwikPen autoinjector with a similar hidden-needle design. Neither requires refrigeration for short-term travel periods (Mounjaro: up to 21 days at room temperature below 30°C; Trulicity: up to 14 days).

Switching Between Mounjaro and Trulicity

When Switching From Trulicity to Mounjaro Makes Sense

A patient on dulaglutide who has not reached their A1C or weight target is a reasonable candidate for tirzepatide. Because both drugs are once-weekly injectables, the transition does not require a washout period. The standard approach is to start tirzepatide at 2.5 mg on the day the next dulaglutide dose would have been due, then titrate per the standard schedule. Switching guidance is supported by the ADA Standards of Care, available at diabetesjournals.org.

The HealthRX clinical team uses the following framework when evaluating a switch from dulaglutide to tirzepatide:

1. Current A1C vs. Target: If A1C remains >0.5 percentage points above goal on dulaglutide 1.5 mg or higher after 6 months, tirzepatide is preferred assuming formulary access.
2. Weight trajectory: If the patient has obesity (BMI >30) or overweight with a metabolic comorbidity and <5% body weight loss on dulaglutide after 6 months, tirzepatide's dual mechanism offers a clear clinical advantage.
3. Cardiovascular disease status: In patients with recent acute coronary syndrome or documented high MACE risk, the REWIND-backed label for dulaglutide remains a defensible choice pending full SURPASS-CVOT publication.
4. Tolerability history: Patients who discontinued a prior GLP-1 agent due to GI side effects may tolerate tirzepatide at conservative titration, but the risk is not eliminated.
5. Cost and coverage: If the patient cannot access tirzepatide due to prior authorization denial, semaglutide 1.0 mg or 2.0 mg may be a closer efficacy match to tirzepatide than continued dulaglutide.

When Switching From Mounjaro to Trulicity Makes Sense

Switching from tirzepatide to dulaglutide is less common from a pure efficacy standpoint, but it does occur. The main drivers are cost (Trulicity may have better formulary placement on certain Medicare Part D plans), supply disruptions, or patient tolerance. If switching down, the clinician should set realistic expectations: A1C and weight outcomes will likely regress from the tirzepatide level, and the patient should be counseled on that explicitly.

Practical Transition Note

Neither the ADA nor the AACE currently publish a specific inter-agent conversion table for GLP-1 class switching, so clinicians rely on pharmacokinetic half-life data. Tirzepatide's mean half-life is approximately 5 days; dulaglutide's is approximately 4.7 days. Both clear within 3 to 4 weeks. For most switches, a simple same-day substitution on the injection day is clinically acceptable. Blood glucose monitoring for the first 2 to 4 weeks after switching is advisable. ADA Standards of Care section on injectables is at diabetesjournals.org.

Cost, Insurance Coverage, and Access

List Prices and Savings Programs

Without insurance, both Mounjaro and Trulicity list for approximately $800 to $1,000 per month in the United States. Eli Lilly manufactures both. The Mounjaro Savings Card program reduces out-of-pocket cost to as low as $25 per month for eligible commercially insured patients, and the Zepbound savings card applies to that formulation for obesity. Trulicity has a similar Lilly Cares program. Medicare Part D coverage varies by plan; GLP-1 agents for weight management remain excluded from Medicare coverage under current statute unless the patient has type 2 diabetes.

Prior Authorization Trends

Commercial insurers increasingly require documented A1C above a threshold (often 8.0%) plus metformin use or intolerance before approving tirzepatide. Trulicity typically faces fewer step-therapy requirements on plans where it is preferred. Clinicians prescribing tirzepatide should document baseline A1C, prior metformin trial, and BMI to support prior authorization requests. CMS coverage determinations for GLP-1 agents are reviewed at cms.gov and summarized by the ADA at diabetesjournals.org.

What the Guidelines Say

The 2024 American Diabetes Association Standards of Medical Care in Diabetes recommend GLP-1 receptor agonists with proven cardiovascular benefit for patients with established atherosclerotic cardiovascular disease, with dulaglutide named as one of those agents based on REWIND. Full ADA 2024 Standards at diabetesjournals.org. For patients where weight loss is a co-primary goal, the ADA guideline notes that tirzepatide offers greater weight reduction than GLP-1-only agents and should be considered when both glycemic and weight targets are relevant.

The American Association of Clinical Endocrinology (AACE) 2023 diabetes algorithm places tirzepatide in the highest efficacy tier for both A1C reduction and weight management, recommending it as a first-line injectable option when the A1C gap to goal exceeds 1.5 percentage points or when substantial weight reduction is needed. Dulaglutide sits in a moderate-efficacy tier alongside other GLP-1 agents. AACE guidelines are available at aace.com.

As the ADA 2024 Standards state directly: "For patients with type 2 diabetes and overweight or obesity where weight management is a priority, a GLP-1 receptor agonist with the highest weight loss efficacy should be considered." Tirzepatide currently holds that position in published head-to-head data.

Side Effects and Contraindications

Shared Side Effects

Both drugs share a GLP-1-mediated GI side-effect profile. Nausea is the most commonly reported event, occurring in 15 to 22% of patients during the titration phase and typically subsiding over 4 to 8 weeks. Vomiting, diarrhea, constipation, and decreased appetite are also reported. Slow titration substantially reduces dropout due to GI effects; skipping dose escalation steps is a practical tool for intolerant patients. GLP-1 GI tolerability data are reviewed at pubmed.ncbi.nlm.nih.gov.

Black Box Warning: Thyroid C-Cell Tumors

Both agents carry a black box warning about the risk of thyroid C-cell tumors, based on rodent carcinogenicity studies. Neither drug should be prescribed to patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). The risk in humans has not been definitively established, but the contraindication applies to both agents. FDA black box warning details at accessdata.fda.gov.

Pancreatitis Risk

Both GLP-1 class agents carry a precautionary note regarding acute pancreatitis. Patients should be instructed to discontinue the medication and seek evaluation if they develop persistent severe abdominal pain. The absolute risk remains low in clinical trials, but the signal exists in post-marketing surveillance data. Patients with a history of pancreatitis were excluded from SURPASS-2 and REWIND.

Quick Comparison Summary

| Feature | Mounjaro (Tirzepatide) | Trulicity (Dulaglutide) | |---|---|---| | Mechanism | Dual GIP/GLP-1 agonist | GLP-1 agonist only | | Max dose | 15 mg/week | 4.5 mg/week | | A1C reduction (max dose, RCT) | -2.46 pp (SURPASS-2) | -1.34 pp (SURPASS-2) | | Weight loss (max dose, RCT) | -11.2 kg (SURPASS-2) | -2.3 kg (SURPASS-2) | | MACE outcome trial | SURPASS-CVOT (pending) | REWIND (HR 0.88, P=0.026) | | Obesity indication | Yes (as Zepbound) | No | | CKD data depth | Moderate | Extensive (AWARD-7) | | Injection frequency | Weekly | Weekly |

For a patient whose A1C remains above 8.0% on metformin and who carries 30 or more pounds of excess weight, tirzepatide's SURPASS-2 profile makes it the stronger pharmacological choice. For a patient with recent MACE or high cardiovascular risk where proven mortality data are non-negotiable today, dulaglutide's REWIND label provides a level of cardiovascular evidence that tirzepatide cannot yet match in published form.